These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1127 related items for PubMed ID: 15647969

  • 1. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E, Lyritis GP, Kosmidis C, Galanos A, Andypas G, Chorianopoulos K, Giagiosis A, Iliadou K, Karagianis A, Katsimichas K, Koskinas A, Matsouka K.
    Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
    [Abstract] [Full Text] [Related]

  • 2. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
    Tascioglu F, Colak O, Armagan O, Alatas O, Oner C.
    Rheumatol Int; 2005 Nov; 26(1):21-9. PubMed ID: 15688191
    [Abstract] [Full Text] [Related]

  • 3. Early effect of nasal salmon calcitonin on the bone marker Crosslaps.
    Ofluoglu D, Karadag-Saygi E, Canbulat C, Gunduz OH, Kul-Panza E, Akyuz G.
    Rheumatol Int; 2006 Feb; 26(4):288-91. PubMed ID: 15875189
    [Abstract] [Full Text] [Related]

  • 4. Salmon calcitonin in prevention of osteoporosis in maintenance dialysis patients.
    Wang SX, Li H.
    Chin Med J (Engl); 2008 Jul 20; 121(14):1280-4. PubMed ID: 18713548
    [Abstract] [Full Text] [Related]

  • 5. Early postmenopausal bone loss is prevented by estrogen and partially by 1alpha-OH-vitamin D3: therapeutic effects of estrogen and/or 1alpha-OH-vitamin D3.
    Gorai I, Chaki O, Taguchi Y, Nakayama M, Osada H, Suzuki N, Katagiri N, Misu Y, Minaguchi H.
    Calcif Tissue Int; 1999 Jul 20; 65(1):16-22. PubMed ID: 10369728
    [Abstract] [Full Text] [Related]

  • 6. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss.
    Reginster JY, Deroisy R, Lecart MP, Sarlet N, Zegels B, Jupsin I, de Longueville M, Franchimont P.
    Am J Med; 1995 May 20; 98(5):452-8. PubMed ID: 7733123
    [Abstract] [Full Text] [Related]

  • 7. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L.
    Menopause; 2013 Jan 20; 20(1):72-8. PubMed ID: 22968256
    [Abstract] [Full Text] [Related]

  • 8. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis.
    Adami S, Passeri M, Ortolani S, Broggini M, Carratelli L, Caruso I, Gandolini G, Gnessi L, Laurenzi M, Lombardi A.
    Bone; 1995 Oct 20; 17(4):383-90. PubMed ID: 8573412
    [Abstract] [Full Text] [Related]

  • 9. Comparison of different treatment modalities for postmenopausal patients with osteopenia: hormone replacement therapy, calcitonin and clodronate.
    Tiraş MB, Noyan V, Yildiz A, Biberoğlu K.
    Climacteric; 2000 Jun 20; 3(2):92-101. PubMed ID: 11910657
    [Abstract] [Full Text] [Related]

  • 10. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial.
    Binkley N, Bolognese M, Sidorowicz-Bialynicka A, Vally T, Trout R, Miller C, Buben CE, Gilligan JP, Krause DS, Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) Investigators.
    J Bone Miner Res; 2012 Aug 20; 27(8):1821-9. PubMed ID: 22437792
    [Abstract] [Full Text] [Related]

  • 11. Discontinuous calcitonin treatment of established osteoporosis--effects of withdrawal of treatment.
    Overgaard K, Hansen MA, Nielsen VA, Riis BJ, Christiansen C.
    Am J Med; 1990 Jul 20; 89(1):1-6. PubMed ID: 2152594
    [Abstract] [Full Text] [Related]

  • 12. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women.
    Downs RW, Bell NH, Ettinger MP, Walsh BW, Favus MJ, Mako B, Wang L, Smith ME, Gormley GJ, Melton ME.
    J Clin Endocrinol Metab; 2000 May 20; 85(5):1783-8. PubMed ID: 10843152
    [Abstract] [Full Text] [Related]

  • 13. Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin.
    Reginster JY, Denis D, Deroisy R, Lecart MP, De Longueville M, Zegels B, Sarlet N, Noirfalisse P, Franchimont P.
    J Bone Miner Res; 1994 Jan 20; 9(1):69-73. PubMed ID: 8154311
    [Abstract] [Full Text] [Related]

  • 14. [Effectiveness of intranasal salmon calcitonin treatment in postmenopausal osteoporosis].
    Kopaliani M.
    Georgian Med News; 2005 Apr 20; (121):38-42. PubMed ID: 15908722
    [Abstract] [Full Text] [Related]

  • 15. Salmon calcitonin in the prevention of bone loss at perimenopause.
    Arnala I, Saastamoinen J, Alhava EM.
    Bone; 1996 Jun 20; 18(6):629-32. PubMed ID: 8806006
    [Abstract] [Full Text] [Related]

  • 16. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
    Hodsman AB, Fraher LJ, Watson PH, Ostbye T, Stitt LW, Adachi JD, Taves DH, Drost D.
    J Clin Endocrinol Metab; 1997 Feb 20; 82(2):620-8. PubMed ID: 9024265
    [Abstract] [Full Text] [Related]

  • 17. Comparison of cyclic and continuous calcitonin regimens in the treatment of postmenopausal osteoporosis.
    Tekeoğlu I, Adak B, Budancamanak M, Demirel A, Ediz L.
    Rheumatol Int; 2005 Dec 20; 26(2):157-61. PubMed ID: 15660234
    [Abstract] [Full Text] [Related]

  • 18. The effect of calcitonin on biochemical markers and zinc excretion in postmenopausal osteoporosis.
    Colpan L, Gur A, Cevik R, Nas K, Sarac AJ.
    Maturitas; 2005 Jul 16; 51(3):246-53. PubMed ID: 15978968
    [Abstract] [Full Text] [Related]

  • 19. A double blind study of intranasal calcitonin for established postmenopausal osteoporosis.
    Kapetanos G, Symeonides PP, Dimitriou C, Karakatsanis K, Potoupnis M.
    Acta Orthop Scand Suppl; 1997 Oct 16; 275():108-11. PubMed ID: 9385282
    [Abstract] [Full Text] [Related]

  • 20. A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers.
    Trovas GP, Lyritis GP, Galanos A, Raptou P, Constantelou E.
    J Bone Miner Res; 2002 Mar 16; 17(3):521-7. PubMed ID: 11874243
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.